Brigatinib Approved, but Treatment Role Uncertain
Copyright policy )Brigatinib Approved, but Treatment Role Uncertain
Abstract The FDA has approved the ALK inhibitor brigatinib for patients with metastatic non-small cell lung cancer who cannot take crizotinib or whose disease worsened despite its use. The decision was based upon results of a phase II study that assessed two drug doses, with overall response rates of 45% and 56% respectively. The drug's effect on overall survival remains unclear, as does the optimal sequence of brigatinib and the three other ALK inhibitors.
Pyridines, United States Food and Drug Administration, Receptor Protein-Tyrosine Kinases, United States, Clinical Trials, Phase II as Topic, Organophosphorus Compounds, Pyrimidines, Crizotinib, Carcinoma, Non-Small-Cell Lung, Humans, Pyrazoles, Anaplastic Lymphoma Kinase, Drug Approval
Pyridines, United States Food and Drug Administration, Receptor Protein-Tyrosine Kinases, United States, Clinical Trials, Phase II as Topic, Organophosphorus Compounds, Pyrimidines, Crizotinib, Carcinoma, Non-Small-Cell Lung, Humans, Pyrazoles, Anaplastic Lymphoma Kinase, Drug Approval
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).4 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!